Humana (NYSE:HUM) Releases FY18 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $13.50-14.00 for the period, compared to the Thomson Reuters consensus estimate of $12.45. The company issued revenue guidance of $55.8-56.4 billion, compared to the consensus revenue estimate of $56.57 billion.

Humana (NYSE HUM) opened at $268.07 on Wednesday. The company has a quick ratio of 1.61, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. Humana has a fifty-two week low of $203.36 and a fifty-two week high of $293.35. The company has a market cap of $36,767.10, a price-to-earnings ratio of 16.07, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Humana had a net margin of 4.55% and a return on equity of 16.13%. The firm had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same period last year, the firm earned $2.34 EPS. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. equities research analysts anticipate that Humana will post 13.84 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be given a $0.50 dividend. This is a boost from Humana’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.75%. Humana’s payout ratio is presently 9.59%.

Humana declared that its board has initiated a share repurchase plan on Thursday, December 14th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the insurance provider to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Humana from $253.00 to $271.00 and gave the company a neutral rating in a research report on Monday. ValuEngine cut shares of Humana from a buy rating to a hold rating in a report on Tuesday, December 19th. Credit Suisse Group initiated coverage on shares of Humana in a report on Thursday, November 2nd. They issued a neutral rating and a $256.00 price objective on the stock. Zacks Investment Research cut shares of Humana from a strong-buy rating to a hold rating in a report on Tuesday, October 17th. Finally, Oppenheimer upped their price objective on shares of Humana from $275.00 to $305.00 and gave the stock an outperform rating in a report on Thursday, February 8th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $270.47.

In related news, SVP Jody L. Bilney sold 7,054 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the transaction, the senior vice president now owns 11,704 shares in the company, valued at $2,901,304.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Timothy S. Huval sold 1,382 shares of the stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total transaction of $340,027.28. Following the transaction, the vice president now owns 11,557 shares in the company, valued at approximately $2,843,484.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,115 shares of company stock worth $2,501,627. 0.80% of the stock is owned by insiders.

WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.

Leave a Reply